

# GLOBAL WHOLEHEALTH PARTNERS CORP.

## Rights to Sell JNJ COVID-19 Vaccine Substantially Raises GWHP's Profile

Rob Goldman  
[rob@goldmanresearch.com](mailto:rob@goldmanresearch.com)

June 11, 2020

### GLOBAL WHOLEHEALTH PARTNERS CORP. (OTC – GWHP - \$0.31)

Industry: Diagnostics

12-18 Mo. Price Target: \$11.20

#### COMPANY SNAPSHOT

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians' offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

#### KEY STATISTICS

Price as of 6/11/21	\$0.31
52 Week High – Low	\$14.50 - \$0.308
Est. Shares Outstanding	78.1M
Market Capitalization	\$24.2M
Average Volume	137,430
Exchange	OTCPK

#### COMPANY INFORMATION

**Global WholeHealth Partners Corporation**  
2227 Avenida Oliva  
San Clemente CA 92673

Web: <https://gwhpcorp.com/>  
Email: [cstrongo@gmail.com](mailto:cstrongo@gmail.com)  
Phone : 714.392.9752

#### INVESTMENT HIGHLIGHTS

**GWHP recently filed an 8-K whereby it has been granted rights from Nunzia Pharmaceutical Inc. (OTC – NUNZ) to distribute and sell the single dose Johnson & Johnson COVID-19 vaccine. The 8-K can be accessed here: <https://bit.ly/3vdiCzc>.**

**In our view, this high-profile event substantially raises the Company's status in the diagnostics space in general and the COVID-19 universe, in specific.** The single dose nature of the vaccine has made this vaccine a popular choice in locales where dual doses are not a realistic option, which is a boon to GWHP, in our view.

**A new study released last week by *Nature* noted that the JNJ vaccine has high levels of protection from COVID-19 variants---the biggest current driver of new global COVID-19 cases.** This news could prompt a migration toward the JNJ vaccine in large global markets.

**Separately, GWHP and AAJ have created an industry-leading set of diagnostics products for the Philippines and the surrounding Pacific Rim countries, where access to critical vaccines is low.** The products to be delivered include the COVID-19 Antigen, COVID-19 Antibody, Dengue Fever, TB, Malaria, and Influenza A & B.

**We have extended our \$11.20 target to 12-18 months, which is based on a typical industry P/E multiple of 20x our 2022E EPS estimates. Given the strength of GWHP's recent news, we believe these shares could return to the \$1.50 mark by the end of summer, as JNJ sales commence.**

## SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

## ANALYST CERTIFICATION

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

## DISCLAIMER

This *Opportunity Research* report was prepared for informational purposes only.

*Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile and may offer greater upside. Since 2020, *Goldman Small Cap Research* was compensated by the Company in the amount of \$7500 for research report and update production, including \$1500 for this research update. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such

information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: [www.goldmanresearch.com](http://www.goldmanresearch.com)